期刊文献+

二甲双胍及甘精胰岛素对子宫内膜癌细胞增殖和凋亡的影响 被引量:1

Effect of metformin and glargine on proliferation and apoptosis of human endometrial cancer cell in vitro
原文传递
导出
摘要 目的探讨二甲双胍(Met)、甘精胰岛素(Gla)或二者联合对人子宫内膜癌Ishikawa细胞增殖和凋亡的影响。方法不同浓度Met、Gla或二者联合干预人子宫内膜癌Ishikawa细胞株不同时间。CCK-8检测细胞增殖,流式细胞仪检测细胞凋亡。结果与对照1组比较,Met各浓度均可抑制Ishikawa细胞增殖,小剂量(5mmol/L)可使增殖率下降18.4%。Met可诱导Ishikawa细胞凋亡,高浓度(20mmol/L)晚期凋亡率升高最显著(26.11%)。Gla可促进人子宫内膜癌Ishikawa细胞增殖,细胞凋亡率降低。Gla联合不同浓度Met,与同浓度同时间Gla干预对比,可抑制增殖,增加凋亡率。结论 Met可抑制人子宫内膜癌Ishikawa细胞增殖,促进其凋亡,并可阻断Gla对人子宫内膜癌细胞的促增殖作用。 Objective To investigate the effect of metformin,glargine or drug combination on the proliferation and apoptosis of Ishikawa cell line.Methods Ishikawa cell was cultured in vitro and intervened with metformin,glargine and drug combination for different time.The rate of cell proliferation was tested by CCK-8 assay,and cell apoptosis were detected by flow cytometer.Results Compared with control 1 group,5,10 and 20 mmol/L metformin could inhibit Ishikawa cell line significantly.The rate of proliferation index was reduced 18.4% by 5 mmol/L metformin intervened.Metformin could induce apoptosis of Ishikawa cell line,and the rate of the most significant late apoptosis increased was 20mmol/L concentration (26.11%).On the contrary,10,100 and 1000 IU/L glargine could induce the cell proliferation and the rate of cell apoptosis was lower.Compared with the 100 IU/L glargine,which combined with different concentrations metformin had higher cell proliferation and lower apoptosis.Conclusion Metformin can inhibit Ishikawa cell line and induce cell apoptosis in vitro.Metformin can stop the effect of glargine on inducing cell proliferation of Ishikawa cell line.
作者 谢颖 赖晓阳
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第6期556-559,共4页 Chinese Journal of Diabetes
基金 江西省自然科学基金(20122BAB205009)
关键词 二甲双胍 甘精胰岛素 细胞增殖 细胞凋亡 Metformin Glargine Cell proliferation Apoptosis
  • 相关文献

参考文献10

  • 1Decensi A,Puntoni M,Goodwin P,et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research, 2010,3 : 1451-1461.
  • 2Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of recep- tor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes, 2000, 49:999-1005.
  • 3Currie CJ, Poole CD, Gale EAM. The influence of glucose- lowering therapies on cancer risk in type 2 diabetes. Diabetolo- gia, 2009, 52:1766-1777.
  • 4Sahra IB, Laurent K, Loubat A, et al. The antidiabetie drug metformin exerts an antitumoral effect in vitro andin vivo through a decrease of eyclin D1 level. Oncogene , 2008, 27: 3576-3586.
  • 5Mayer D, Shukla A, Enzmann H. Proliferative effects of insu- lin analogues on mammary epithelial cells. Arch Physiol Bio- chem, 2008,114: 38-44.
  • 6Origin Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012,367:319-328.
  • 7Zhuang YX,Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kipl or p21Cipl. Journal of Molecular Signaling, 2008, 3:18.
  • 8Pavelic J, Matijevic T, Knezevic J. Biological & physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res, 2007, 125:511-522.
  • 9López-Calderero I, Scinchez Chcivez E, Garcia-Carbonero R. The insulin-like growth factor pathway as a target for cancer therapy. Clin Transl Oncol, 2010 , 12:326-338.
  • 10Vivanco I, Sawyer CI. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002,2:489-501.

同被引文献5

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部